These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 4824675)

  • 1. Parkinson's disease and striatal dopamine: in vivo morphological evidence for the presence of dopamine in the human brain.
    Constantinidis J; Siegfried J; Frigyesi TL; Tissot R
    J Neural Transm; 1974; 35(1):13-22. PubMed ID: 4824675
    [No Abstract]   [Full Text] [Related]  

  • 2. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
    Bernheimer H; Birkmayer W; Hornykiewicz O; Jellinger K; Seitelberger F
    J Neurol Sci; 1973 Dec; 20(4):415-55. PubMed ID: 4272516
    [No Abstract]   [Full Text] [Related]  

  • 3. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 4. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.
    Leenders KL; Palmer AJ; Quinn N; Clark JC; Firnau G; Garnett ES; Nahmias C; Jones T; Marsden CD
    J Neurol Neurosurg Psychiatry; 1986 Aug; 49(8):853-60. PubMed ID: 3091770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influencing of Parkinson's syndrome via intervention in the dopamine metabolism].
    Korten JJ; van Rossum JM
    Ned Tijdschr Geneeskd; 1973 Feb; 117(8):296-305. PubMed ID: 4350090
    [No Abstract]   [Full Text] [Related]  

  • 7. Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine.
    Price KS; Farley IJ; Hornykiewicz O
    Adv Biochem Psychopharmacol; 1978; 19():293-300. PubMed ID: 696462
    [No Abstract]   [Full Text] [Related]  

  • 8. [Striatal dopamine availability in Parkinson's disease--with reference to the wearing-off phenomenon].
    Indo T
    Rinsho Shinkeigaku; 1984 Oct; 24(10):1008-16. PubMed ID: 6518691
    [No Abstract]   [Full Text] [Related]  

  • 9. Striatal dopamine distribution in parkinsonian patients during life.
    Nahmias C; Garnett ES; Firnau G; Lang A
    J Neurol Sci; 1985 Jul; 69(3):223-30. PubMed ID: 3928823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in brain opiate receptors in Parkinson's disease.
    Reisine TD; Rossor M; Spokes E; Iversen LL; Yamamura HI
    Brain Res; 1979 Sep; 173(2):378-82. PubMed ID: 226215
    [No Abstract]   [Full Text] [Related]  

  • 11. Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings.
    Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    J Neural Transm; 1974; 35(2):93-116. PubMed ID: 4844103
    [No Abstract]   [Full Text] [Related]  

  • 12. Dopamine receptors in Parkinson's disease.
    Hassan MN; Thakar JH
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(2-3):173-82. PubMed ID: 3290993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.
    Guttman M; Seeman P
    J Neural Transm; 1985; 64(2):93-103. PubMed ID: 2934514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.
    Kish SJ; Shannak K; Hornykiewicz O
    N Engl J Med; 1988 Apr; 318(14):876-80. PubMed ID: 3352672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical analysis of caudate nucleus biopsy samples from parkinsonian patients.
    Goldstein M; Lieberman AN; Helmer E; Koslow M; Ransohoff J; Elsworth JD; Roth RH; Deutch AY
    Ann Neurol; 1988 Nov; 24(5):685-8. PubMed ID: 2904793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of dopamine in the physiology and pathology of the basal ganglia].
    Arushanian EB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(4):595-603. PubMed ID: 4341763
    [No Abstract]   [Full Text] [Related]  

  • 17. Seasonality of striatal dopamine synthesis capacity in Parkinson's disease.
    Kaasinen V; Jokinen P; Joutsa J; Eskola O; Rinne JO
    Neurosci Lett; 2012 Nov; 530(1):80-4. PubMed ID: 23041046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease.
    Kish SJ; Shannak K; Rajput A; Deck JH; Hornykiewicz O
    J Neurochem; 1992 Feb; 58(2):642-8. PubMed ID: 1729408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.